AndrewAlexanderSandbox1

From Proteopedia

Jump to: navigation, search

Contents

Pyruvate Kinase

Pyruvate Kinase is an enzyme that is involved in glycolysis. Pyruvate kinase’s function is to catalyze the last step of glycolysis; thereby, generating the second ATP of glycolysis and pyruvate. It is able to catalyze this step by transferring the phosphate group from phosphoenolpyruvate (PEP) to ADP [1].

PDB ID 2vgb

Drag the structure with the mouse to rotate
2vgb, resolution 2.73Å ()
Ligands: , , ,
Activity: Pyruvate kinase, with EC number 2.7.1.40
Related: 1liy, 1liu, 1liw, 1lix
Resources: FirstGlance, OCA, RCSB, PDBsum
Coordinates: save as pdb, mmCIF, xml



Structure

This particular protein is found in Homo sapiens and has the abbreviation PK. Pyruvate kinase belongs to the all beta proteins class and has the PK beta-barrel domain-like fold. It belongs to the PK beta-barrel domain-like superfamily and pyruvate kinase beta-barrel domain family[2].

Though pyruvate kinase is classified into all beta proteins, pyruvate kinase's comprises of both alpha helices and beta sheets. In the quaternary structure of pyruvate kinase, it can be observed to have in humans. Thus, this enzyme is tetrameric with on each domain for the and Mg2+ ligands to bind to. There are four types of tissue-specific isozymes: L (liver), R (red blood cells), M1 (muscle, heart, and brain), and M2 (early fetal tissue)[3].

Mechanism

[4] catalyzes the final reaction of glycolysis. It couples the free energy of PEP cleavage to the generation of ATP during the synthesis of the final product, pyruvate. This reaction necessitates one K+ and two Mg2+ cations to be used in two steps. The first step is the nucleophilic attack of the PEP phosphorous atom by β-phosphoryl oxygen of ADP; this step displaces enolpyruvate while forming ATP. In the second step, enolpyruvate tautomerizes to pyruvate [5]. The formation of a high-energy intermediate by enolase in the 9th reaction of glycolysis allows for the synthesis of ATP in this reaction. Though the hydrolysis of 2PG is insufficient in driving the synthesis of ATP, the dehydration of 2PG allows for such a reaction to occur by forming a high-energy intermediate. The high potential of PEP reflects the large release of energy that occurs with the conversion of enolpyruvate to its keto tautomer, pyruvate [6].

Kinetics and Regulation

In the glycolytic cycle, there are three compounds that have a large negative ∆G which includes the reaction pyruvate kinase catalyzes. Due to these three steps regulating the overall activity of the cycle, they are generally irreversible in vivo. Through numerous studies, the activity of pyruvate kinase has been found to be regulated by these effectors.


a. Phosphoenolpyruvate, the substrate, can impact enzymatic activity by enhancing the reaction by allowing the process to operate faster with more substrate present.

b. ATP and pyruvate have been found to be a negative allosteric inhibitor.

c. Alanine has also been found to be a negative allosteric modulator [7].


This reaction, although appearing reversible, is essentially irreversible under physiological conditions, thus helping control the metabolic flux in glycolysis. Through allosteric regulation, the PEP binding site is distorted by 29 degrees on transition from the R-state to the T-state. Pyruvate kinase is primarily allosterically regulated [8]. Allosteric regulation of enzyme activity is a mechanism for finely tuning biochemical reaction pathways in order to maintain an appropriate balance of intracellular substrate and product concentrations. Allosteric processes also allow an enzyme's activity to be coordinated with other cellular reactions and signaling pathways.Through site directed mutagenisis studies, Lys382 is suggested to be involved in both activator binding and in the allosteric transition mechanism. These domain interfaces are critical for the trasnition. Tey couple changes in the tertiary and quaternary structures in fructose 1,6 biphosphate binding sites for pyruvate kinase.

The allosteric site is located 40 å from the active site and is entirely located in the enzyme regulatory (C) domain. A phosphate-binding site for the allosteric activator is created by residues encoded by a region of the gene that corresponds to spliced exons of mammalian isozymes [9]. FBP activation induces several conformational changes among active-site sidechains through a mechanism that is most likely to involve significant domain motions. The conformational differences observed between the active sites of inactive and fully active Pyruvate Kinase enzymes is in agreement with the thermodynamic mechanism of allosteric activation through a metal relay that increases the affinity of the enzyme for its phosphoenolpyruvate substrate.


Without a high K+ concentration, the kinetic mechanism of pyruvate kinase changes from random to ordered with phosphoenolpyruvate as the first substrate. Vmax with K+ was about 400 times higher than a wild type sample without K+. In the presence of K+, the affinities for phosphoenolpruvate and ADP were 2-6 times higher than in the abscence of K+. This shows that K+ is involved in the acquisition of the active conformation of the enzyme, allowing either phosphoenolpyruvate or ADP to bind independently, but without K+, ADP cannot bind to the enzyme until phosphoenolpyruvate forms a competent active site for an ordered mechanism. Wild type pyruvate kinase without K+ has an ordered rapid equilibrium kinetic mechanism that shows Vmax to be 0.8 +/- -.04 umol/min mg with a kcat of 3.2 s^-1. When the wild-type pyruvate kinase has K+, it is in a random rapid equilibrium kinetic mechanism with a Vmax of 299 +/- 11 umol/min mg with a kcat of 1182 [10].

As indicated earlier, phosphoenolpyruvate can enhance the activity of the reaction by adding into the enzyme because it is the rate limiting step. The enzyme follows hyperbolic kinetics. Experiments found that no incorporation was found in the reaction, indicating a random, rapid dissociation of the products. This, then, assumes that the products inhibit the enzyme’s reaction by simply reversing the reaction. Both pyruvate and ATP have been shown to be non-competitive inhibitors of pyruvate kinase [11].

With or without K+, oxalate is a noncompetitive inhibitor of ADP-Mg2+. It will form a nonproductive ternary complex which diminishes Vmax without altering the binding of ADP-Mg2+ [12].

Pyruvate Kinase Deficiency

Pyruvate kinase deficiency is the most frequent enzyme abnormality of glycolysis that causes hemolytic anemia. In cells that lack mitochondria, this deficiency is especially harmful, because these cells must use anaerobic glycolysis as their sole source of energy because the TCA cycle is not available. Red blood cells, in a state of pyruvate kinase deficiency, rapidly become deficient in ATP and can undergo hemolysis.This is transmitted as an autosomal recessive trit. The severity of hemolysis is extremely variable such as a mild case to life-threatening neonatal anaemia requiring transfusions. Over one hundred eighty different mutations have been discovered in relation to this deficiency with most being autosomal recessive, but a few strands are autosomal dominant. The deficiency causes red blood cells to deform into echinocytes on peripheral blood smears. This causes the buildup of reaction intermediates which can also increase the level of 2,3-bisphosphoglycerate in the cells. This causes a rightward shift in the hemoglobin oxygen saturation curve, which means that there is a decreased oxygen affinity for the hemoglobin and earlier oxygen unloading than under normal conditions [13].

Additional Resources

For additional information, see: Carbohydrate Metabolism

References

  1. ↑ Voet, Donald, Judith G. Voet, and Charlotte W. Pratt. Fundamentals of Biochemistry: Life at the Molecular Level. 3rd ed. Hoboken, NJ: John Wiley & Sons, Inc., 2008, 501-503.
  2. ↑ authors, The scop. "Structural Classification of Proteins". 2009. 2/26 2010. <http://scop.berkeley.edu/data/scop.b.c.jh.b.b.d.html>.
  3. ↑ authors, The scop. "Structural Classification of Proteins". 2009. 2/26 2010. <http://scop.berkeley.edu/data/scop.b.c.jh.b.b.d.html>.
  4. ↑ Robergs, Robert. "Exercise-Induced Metabolic Acidosis: Where do the Protons come from?". 2009. 2/27 2010. <http://www.sportsci.org/jour/0102/rar.htm>.
  5. ↑ Voet, Donald, Judith G. Voet, and Charlotte W. Pratt. Fundamentals of Biochemistry: Life at the Molecular Level. 3rd ed. Hoboken, NJ: John Wiley & Sons, Inc., 2008, 501-503.
  6. ↑ Voet, Donald, Judith G. Voet, and Charlotte W. Pratt. Fundamentals of Biochemistry: Life at the Molecular Level. 3rd ed. Hoboken, NJ: John Wiley & Sons, Inc., 2008, 501-503.
  7. ↑ Dann LG, Britton HG. Kinetics and mechanism of action of muscle pyruvate kinase. Biochem J. 1978 Jan 1;169(1):39-54. PMID:629752
  8. ↑ Mattevi A, Bolognesi M, Valentini G. The allosteric regulation of pyruvate kinase. FEBS Lett. 1996 Jun 24;389(1):15-9. PMID:8682196
  9. ↑ Jurica MS, Mesecar A, Heath PJ, Shi W, Nowak T, Stoddard BL. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure. 1998 Feb 15;6(2):195-210. PMID:9519410
  10. ↑ Oria-Hernandez J, Cabrera N, Perez-Montfort R, Ramirez-Silva L. Pyruvate kinase revisited: the activating effect of K+. J Biol Chem. 2005 Nov 11;280(45):37924-9. Epub 2005 Sep 7. PMID:16147999 doi:10.1074/jbc.M508490200
  11. ↑ Dann LG, Britton HG. Kinetics and mechanism of action of muscle pyruvate kinase. Biochem J. 1978 Jan 1;169(1):39-54. PMID:629752
  12. ↑ Oria-Hernandez J, Cabrera N, Perez-Montfort R, Ramirez-Silva L. Pyruvate kinase revisited: the activating effect of K+. J Biol Chem. 2005 Nov 11;280(45):37924-9. Epub 2005 Sep 7. PMID:16147999 doi:10.1074/jbc.M508490200
  13. ↑ Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G. Pyruvate kinase deficiency: the genotype-phenotype association. Blood Rev. 2007 Jul;21(4):217-31. Epub 2007 Mar 13. PMID:17360088 doi:10.1016/j.blre.2007.01.001

Proteopedia Page Contributors and Editors (what is this?)

Andrew Alexander

Retrieved from "http://proteopedia.org/wiki/index.php/AndrewAlexanderSandbox1"
Personal tools